(72 days)
- Relaxation of Muscle Spasm
- Prevention of Retardation of disuse atrophy.
- Increasing local blood circulation
- Muscle Re-education.
- Immediate postsurgical stimulation of calf muscles to prevent venous thrombosis.
- Maintaining or increasing range of motion.
Not Found
The provided text is a 510(k) premarket notification approval letter from the FDA to LSI International for their devices MS300 and MS400. This document focuses on the regulatory aspects of device approval (substantial equivalence to predicate devices) and does not contain information about specific acceptance criteria, study methodologies, or performance data of the MS300 and MS400 devices.
Therefore, I cannot provide the requested information regarding acceptance criteria, study details, sample sizes, ground truth establishment, or expert qualifications as it is not present in the provided text.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of three human profiles facing right, stacked on top of each other. The profiles are rendered in a simple, flowing line style. The logo is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JAN 28 1999
Mr. James C. Lane CEO, Regulatory Affairs LSI International 8849 Bond Overland Park, Kansas 66214
Re: K984021 Trade Name: MS300 K984113 Trade Name: MS400 Regulatory Class: II Product Code: IPF November 3 and 5, 1998 Dated: November 12 and 17, 1998 Received:
Dear Mr. Lane:
We have reviewed your Section 510(k) notifications of intent to market the devices referenced above and we have determined these devices are substantially equivalent (for the indications for use stated in the enclosures) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the devices, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your devices are classified (see above) into either class II (Special Controls) or class III (Premarket Approval), they may be subject to such additional controls. Existing major requlations affecting your devices can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. ਕੇ substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your devices in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
Page 2 - Mr. James C. Lane
This letter will allow you to begin marketing your devices as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your devices to legally marketed predicate devices results in a classification for your devices and thus, permits your devices to proceed to the market.
If you desire specific advice for your devices on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your devices, please contact the Office of Compliance at (301) 594-4639. Also, please note ens regulation entitled, "Misbranding by reference to
premarket notification" (21 CRR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Celia M. Witten, Ph.D., M.D.
Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosures
{2}------------------------------------------------
510(k) Number (if known):_____________________________________________________________________________________________________________________________________________________
ー
. •
Device Name: MS400
Indications For Use:
- Relaxation of Muscle Spasm I)
- Prevention of Retardation of disuse atrophy. 2)
- Increasing local blood circulation 3)
- Muscle Re-education. 4)
- Immediate postsurgical stimulation of calf muscles ર) to prevent venous thrombosis.
- Maintaining or increasing range of motion. 6)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| --------------------- | -- |
Division of General Restorative Devices 19844113510(k) Number
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use
ব
(Optional Format 1-2-96)
.. ...
§ 890.5850 Powered muscle stimulator.
(a)
Identification. A powered muscle stimulator is an electrically powered device intended for medical purposes that repeatedly contracts muscles by passing electrical currents through electrodes contacting the affected body area.(b)
Classification. Class II (performance standards).